A Double-Blind comparison of Empirical Oral and Intravenous Antibiotic Therapy for Low-risk Febrile Patients with Neutropenia during Cancer Chemotherapy
Alison Freifeld, Donna Marchigiani, Thomas Walsh, et. al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD
Source: New England Journal of Medicine, Volume 341, No 5 (July), 1999
Fever and neutropenia (low white count) are major complications among cancer patients treated with intensive cytotoxicchemotherapy. Serious and potentially life-threatening medical complications, such as hypotension, pulmonary compromise, andaltered mental status, may occur. Prompt and adequate treatment of these patients with empirical intravenous therapy withbroad-spectrum antibiotics is the standard of care. However, not all patients have the same risk for life threatening systemicinfections. Patients with fever and neutropenia of no more than 7 to 10 days and without any other underlying conditions maybe considered as low-risk. Therefore, aggressive inpatient treatment with intravenous antibiotics may be unnecessary. Freifeldet al. undertook a multicenter, randomized, double-blinded, placebo-controlled study to determine whether oral empiricaltherapy is as effective as intravanous therapy in low-risk patients with granulocytopenia.
Patients (age ranged from 5 to 74) with cancer who had fever with neutropenia were eligible if their neutropenia was expectedto resolve within 10 days after the onset of fever and if they did not have hemodynamic instability, abdominal pain, nausea andvomiting, diarrhea, neurologic or mental-status changes, intravascular-catheter infection, catheter-tunnel infection, or a newpulmonary infiltrate. Patients were randomly assigned to receive either the oral regimen consisting of 30 mg/kg of ciprofloxacin(Cipro) per day in three divided doses plus 40mg/kg of amoxicillin-calvulanate (Augmentin) in three divided doses or theintravenous regimen consisting of 90 mg/kg of ceftazidime (Fortaz) in three divided doses. Each active regimen was paired witha placebo preparation.
A total of 232 episodes of neutropenia (defined as <500 neutrophils per cubic millimeter) were included with 116 episodes ineach group. Treatment was successfully administered without modifications in approximately two thirds of patients in eachgroup. There were no deaths. The efficacies of the oral and intravenous regimens were similar (71% vs. 59%, p=0.07). Feverof unexplained origin was successfully treated in 85% of the episodes in the oral-therapy group and 90% of the episodes in theintravenous-therapy group. For patients with documented infection, oral-therapy was successful in 41% of the episodes vs.33% of those treated in the intravenous-therapy group (p=0.4). Adverse effects appeared to be comparable, except fordiarrhea, which was more common in the oral-therapy group.
In low-risk hospitalized patients with cancer who have fever and neutropenia, empirical oral-therapy with Cipro plus Augmentinwas found to be as effective as intravenous-therapy with Fortaz. However, how to use these regimens appropriately inindividual patients remains challenging. Further studies may be necessary before adopting this oral regimen for outpatient use.
Frequently Asked Questions
National Cancer Institute